Home › Opioid Overdose › NCT06513156
Continuum of Care in Hospitalized Patients With Opioid/Stimulant Use Disorder and Infectious Complications From Drug Use
Continuum of Care in Hospitalized Patients With Opioid or Stimulant Use Disorder and Infectious Complications of Drug Use - Substance Use/ID Integrated Clinic vs. TAU to Prevent Infection Related Readmission
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: 1. Age ≥ 18 years 2. Admitted to study hospital (defined as hospitalized with a primary team that is not Emergency Medicine) 3. Injection opioid or stimulant use in past 90 days - per patient self-report 4. Active suspected or confirmed qualifying infection (see list) at time of admission. Qualifying infections: * Non-vertebral osteomyelitis * Vertebral osteomyelitis or discitis * Epidural, subdural, or extradural abscess * Intracranial or intraspinal abscess * Native joint septic arthritis * Prosthetic joint septic arthritis * Blood stream infection (bacterial or fungal) * Native valve Endocarditis * Prosthetic valve endocarditis * Cardiac Implantable electronic device infection * Infectious pseudoaneurysm and aneurysm * Infected vascular graft * Septic venous thrombosis * Skin and Soft tissue infection (cellulitis, skin abscess, necrotizing fasciitis) * Infected skin ulcer * Orthopedic hardware infection * Muscle abscess/myositis * Central nervous system infection (bacterial or fungal) * Bacterial or fungal ophthalmologic infection * Other abscess * Pulmonary septic emboli * Other acute bacterial or fungal infection deemed appropriate by site study team Exclusion Criteria: * 1\. Infection due to a cause other than injection drug use, per determination of a site PI. 2\. Inability to provide consent due to circumstance (e.g., sedated, intubated), language, or cognitive impairment. 3\. Unwilling to provide informed consent 4. Unable to receive potential interventions due to geography 5. On comfort measures or planned for discharge to hospice care 6. Incarcerated at the time of hospitalization 7. Other criteria at the discretion of the site investigator
About the study
This is a two-group randomized controlled trial conducted at five hospitals across the U.S. designed to test the effectiveness of an Integrated infectious diseases/Substance Use Disorder outpatient clinic (IC) compared to treatment as usual aimed at reducing infection related readmissions and improving health outcomes in people hospitalized with an infection related to injecting opioids or stimulants.
What is being tested
- Integrated Infectious Diseases and Substance Use Disorder Clinic (IC) (behavioral)
Sponsor: Elana Rosenthal · Participants: 304 · Started: Oct 1, 2024
Contact the study team
- Rachel Silk · Phone: 301-326-7652
Official record on ClinicalTrials.gov — NCT06513156
Locations in the U.S.
| District of Columbia | George Washington University, Washington D.C. |
| Georgia | Emory University, Atlanta |
| Maryland | University of Maryland Baltimore, Baltimore |
| West Virginia | West Virginia University, Morgantown |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.